 BioCardia BCDA, a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board DSMB is expected to report on a prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial, which will be available for release on Tuesday, March 31, 2020. BioCardia will host a conference callwebcast to provide updates on the CardiAMP Heart Failure Trial featuring national co-principal investigators, Amish Raval, MD, of the University of Wisconsin and Carl Pepine, MD, of the University of Florida, Gainesville, on Tuesday, March 31 at 4:15 p.m. ET. A replay of the webcast will be available for a limited time on the BioCardia website following the presentation. 